Rasagiline prodrug - Guangzhou Henovcom Bioscience
Alternative Names: HNC-364Latest Information Update: 18 May 2026
At a glance
- Originator Guangzhou Henovcom Bioscience
- Class Amines; Antiparkinsonians; Indans; Small molecules
- Mechanism of Action Monoamine oxidase B inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Parkinson's disease
Most Recent Events
- 08 May 2026 Guangzhou Henovcom Bioscience initiates enrolment in a phase I pharmacokinetic trial (In volunteers) in the US (NCT06798519)
- 28 Sep 2025 No recent reports of development identified for phase-I development in Parkinson's-disease(In volunteers) in USA (IM, Injection)
- 23 Sep 2025 Rasagiline prodrug is still in phase-I clinical trials in Parkinson's disease (In volunteers) in USA (IM) (NCT05523570)